You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康斥3.6億美元於愛爾蘭建廠
阿思達克 09-21 15:35
阿斯利康(AZN.US)將投資3.6億美元在愛爾蘭興建工廠,以生產活性藥物成分(API)或其他藥物主要成份。 阿斯利康於7月完成以390億美元收購罕見疾病藥物製造商Alexion,後者擁有大量癌症、心臟病、糖尿病及新冠疫苗產品線,同時亦有數款藥物正在進行測試。 阿斯利康表示,今次設廠將支持後期開發及早期商業供應的工作,而該廠房亦可進一步開發以生產新型抗癌藥物-抗體藥物複合體(ADCs)及寡核(甘)酸(Oligonucleotide)等治療方法。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account